Zandberg DP, et al. - Researchers evaluated durvalumab, an anti-programmed death ligand 1 (PD-L1) monoclonal antibody, as monotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and PD-L1 -high expression in the international, multi-institutional, single-arm, phase 2 HAWK study. Durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months was provided to immunotherapy-naïve patients with confirmed PD-L1-high tumor cell expression (defined as patients with ≥25% of tumor cells expressing PD-L1 [TC ≥ 25%] using the VENTANA PD-L1 [SP263] Assay). These patients displayed anti-tumor activity with acceptable safety in these patients. Numerically higher response rate and survival were evident for HPV-positive patients vs HPV-negative patients in an ad hoc analysis.